Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) - Total Liabilities
Based on the latest financial reports, Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) has total liabilities worth NT$1.23 Billion TWD (≈ $38.60 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Chunghwa Chemical Synthesis & Biotech Co to assess how effectively this company generates cash.
Chunghwa Chemical Synthesis & Biotech Co Ltd - Total Liabilities Trend (2008–2024)
This chart illustrates how Chunghwa Chemical Synthesis & Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Chunghwa Chemical Synthesis & Biotech Co liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Chunghwa Chemical Synthesis & Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Chunghwa Chemical Synthesis & Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Astra Exploration Inc
V:ASTR
|
Canada | CA$189.01K |
|
Foodnamoo. Inc
KQ:290720
|
Korea | ₩65.38 Billion |
|
Ihlas Holding AS
IS:IHLAS
|
Turkey | TL18.80 Billion |
|
Crown Seal Public Company Limited
BK:CSC
|
Thailand | ฿899.06 Million |
|
Apex Science & Engineering Corp
TW:3052
|
Taiwan | NT$8.41 Billion |
|
Great Boulder Resources Ltd
AU:GBR
|
Australia | AU$1.84 Million |
|
Epitomee Medical Ltd
TA:EPIT
|
Israel | ILA6.32 Million |
|
Daekyo
KO:019680
|
Korea | ₩297.83 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Chunghwa Chemical Synthesis & Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 1762 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chunghwa Chemical Synthesis & Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chunghwa Chemical Synthesis & Biotech Co Ltd (2008–2024)
The table below shows the annual total liabilities of Chunghwa Chemical Synthesis & Biotech Co Ltd from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.41 Billion ≈ $44.29 Million |
-22.82% |
| 2023-12-31 | NT$1.82 Billion ≈ $57.38 Million |
+32.84% |
| 2022-12-31 | NT$1.37 Billion ≈ $43.20 Million |
-7.76% |
| 2021-12-31 | NT$1.49 Billion ≈ $46.83 Million |
+129.23% |
| 2020-12-31 | NT$648.48 Million ≈ $20.43 Million |
-54.45% |
| 2019-12-31 | NT$1.42 Billion ≈ $44.85 Million |
+15.05% |
| 2018-12-31 | NT$1.24 Billion ≈ $38.99 Million |
-23.93% |
| 2017-12-31 | NT$1.63 Billion ≈ $51.25 Million |
+70.43% |
| 2016-12-31 | NT$954.48 Million ≈ $30.07 Million |
-5.20% |
| 2015-12-31 | NT$1.01 Billion ≈ $31.72 Million |
-36.74% |
| 2014-12-31 | NT$1.59 Billion ≈ $50.14 Million |
+19.74% |
| 2013-12-31 | NT$1.33 Billion ≈ $41.88 Million |
-0.80% |
| 2012-12-31 | NT$1.34 Billion ≈ $42.21 Million |
+91.80% |
| 2011-12-31 | NT$698.59 Million ≈ $22.01 Million |
+1.57% |
| 2010-12-31 | NT$687.80 Million ≈ $21.67 Million |
-38.48% |
| 2009-12-31 | NT$1.12 Billion ≈ $35.22 Million |
-22.31% |
| 2008-12-31 | NT$1.44 Billion ≈ $45.34 Million |
-- |
About Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more